@article{91c0e58732de4bf6bf9c0844b1f4848b,
title = "Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity",
keywords = "B-ALL, CD19 CAR T cells, ICANS, IMMUNOBIOLOGY, Cytotoxic T cells, NEOPLASIA, Lymphoid Leukemias: Immunotherapeutic approaches, inducible Caspase 9, safety switch",
author = "Foster, {Matthew C.} and Barbara Savoldo and Winnie Lau and Clio Rubinos and Natalie Grover and Paul Armistead and James Coghill and Hagan, {Robert S.} and Kaitlin Morrison and Buchanan, {Faith Brianne} and Catherine Cheng and Spencer Laing and Anastasia Ivanova and John West and Aaron Foster and Jonathan Serody and Gianpietro Dotti",
note = "Funding Information: This work was supported in part by Leukemia & Lymphoma Society Translational Research (TRP 6536-18) (B.S.) and The V Foundation (T2017-006) (B.S.). The production of CAR T cells was supported in part by the University Cancer Research Fund and by Bellicum Pharmaceuticals. Funding Information: Rimiducid was provided by Bellicum Pharmaceuticals. The authors acknowledge the patients as well as Paul Eldridge, Kathryn Mackay, Desirae Shelley, and the staff of the Lineberger Advanced Cellular Therapeutics Facility (University of North Carolina, Chapel Hill, NC). This work was supported in part by Leukemia & Lymphoma Society Translational Research (TRP 6536-18) (B.S.) and The V Foundation (T2017-006) (B.S.). The production of CAR T cells was supported in part by the University Cancer Research Fund and by Bellicum Pharmaceuticals.",
year = "2021",
month = jun,
day = "10",
doi = "10.1182/blood.2021010784",
language = "English (US)",
volume = "137",
pages = "3306--3309",
journal = "Blood",
issn = "0006-4971",
publisher = "Elsevier B.V.",
number = "23",
}